MANAGEMENT TEAM
Richard Shimkets, PhD. serves as the President and CEO of Abeome Corporation. Prior to joining Abeome, he served as Vice President of Drug Discovery and Vice President of Scientific Development for CuraGen Corporation. He developed and managed partnerships with Genetech, Biogen, Bayer, and other biotechnology and pharmaceutical companies.
Richard Meagher, PhD, is Abeome's scientific founder and CSO and Distinguished Professor at the University of Georgia in the Department of Genetics. He is the inventor of Abeome's DISH platform and is established as a world-renowned expert in plant genetics and phyto-remediation. Dr. Meagher did his post-doc work at UCSF under Dr. Herbert Boyer, co-founder of Genentech.
Mohamed Shoreibah, PhD. serves as Director of Research and is primarily responsible for protein and antibody analysis and leads the Ovarian Cancer development project. Prior to joining Abeome, he worked at Amgen as Process Development Scientist and has expertise in recombinant protein expression and purification and protein glycosylation.
BOARD OF DIRECTORS
Kirby Alton, PhD, Chairman, was one of the original Amgen scientists (1981) and from 1983 through his retirement in 1999 was head of Amgen product development serving as Senior VP of Development. During this time, Amgen brought its first products to market; Epogen and Neupogen. Dr. Alton had responsibility for global pre-clinical and clinical research and regulatory activities.
John Richard is currently Managing Partner of Georgia Venture Partners. Mr. Richard has over 25 years experience founding, managing, and funding biotechnology businesses. He currently serves on the board of Targacept, Inc. (NASDAQ:TRGT) and several private biotechnology companies.
John Richard is currently Managing Partner of Georgia Venture Partners. Mr. Richard has over 25 years experience founding, managing, and funding biotechnology businesses. He currently serves on the board of Targacept, Inc. (NASDAQ:TRGT) and several private biotechnology companies.
Diana Murphy currently serves as Managing Director for Rocksolid Holdings, LLC in Sea Island, GA and also sits on the board of Landstar Systems in
Jacksonville, FL, the Georgia Research Alliance
Venture Fund, and other privately-held
companies.
James E. Pitts III has a long career in real estate development and is currently owner and President of real estate development entities Randcor, Inc and Randcor Management Inc. of Atlantic Beach, FL.
Lewis Scruggs is CEO of A I Insurance Group in Watkinsville, GA, and serves as the Company Treasurer.
Lewis Scruggs is CEO of A I Insurance Group in Watkinsville, GA, and serves as the Company Treasurer.
Paul Steinfeld is the former Chairman and CEO of Shelby Williams Industries (NYSE company) and currently serves as Managing Director of Longbow Group LLC, a private investment management firm. In addition, Mr. Steinfeld is the Honorary Consul for the Republic of Slovenia.
Rocky (William) Huffman, Jr. is President of THF, Inc, a real estate development and investment company and serves on the board of Panda Energy International, Inc. Mr. Huffman former ly was President of Huffman & Associates, an independent insurance agency that was acquired by Brown & Brown, Inc.SCIENTIFIC ADVISORY BOARD
Richard Meagher, PhD, chairs Abeome's scientific advisory board and is the founder and CSO and Distinguished Professor at the University of Georgia in the Department of Genetics. He is the inventor of Abeome's DISH platform and is established as a world-renowned expert in plant genetics and phyto-remediation. Dr. Meagher did his post-doc work at UCSF under Dr. Herbert Boyer, co-founder of Genentech.
Herb Heyneker, PhD, was one of the original scientists at Genentech after his post-doc work in the laboratory of Herb Boyer at UCSF. Dr. Heyneker has served in a number of executive R&D positions and co-founded several biotech companies over the years.
Christine Debouck, PhD, President of Ardennes Biosciences LLC and formerly Senior VP in R&D at GlaxoSmithKline, is renowned for her expertise in target validation, disease knowledge and compound characterizations in pre-clinical and clinical development, and biomarker evaluation with an emphasis in oncology and infectious diseases.
Jeff Boyd, PhD, Chief Scientific Officer at Fox Chase Cancer Center in Philadelphia has an international reputation as one of the leading scientists in the study of molecular genetics of women's cancers. His long-term research has focused on molecular genetics of ovarian cancer.
Herb Heyneker, PhD, was one of the original scientists at Genentech after his post-doc work in the laboratory of Herb Boyer at UCSF. Dr. Heyneker has served in a number of executive R&D positions and co-founded several biotech companies over the years.
Christine Debouck, PhD, President of Ardennes Biosciences LLC and formerly Senior VP in R&D at GlaxoSmithKline, is renowned for her expertise in target validation, disease knowledge and compound characterizations in pre-clinical and clinical development, and biomarker evaluation with an emphasis in oncology and infectious diseases.
Jeff Boyd, PhD, Chief Scientific Officer at Fox Chase Cancer Center in Philadelphia has an international reputation as one of the leading scientists in the study of molecular genetics of women's cancers. His long-term research has focused on molecular genetics of ovarian cancer.
Linda Matsuuchi, PhD, Associate Director of the Life Sciences Institute at the University of British Columbia has a distinguished research career focused on intracellular trafficking and cell signaling of specific membrane receptors on the cell surface of B lymphocytes.
Jack Sisley, MD, served 14 years in private practice in General Surgery and Surgical Oncology. Immediately prior to that, Dr. Sisley served as Assoc. Prof. of Surgery in Augusta, GA at MCG division of Surgical Oncology.
Jack Sisley, MD, served 14 years in private practice in General Surgery and Surgical Oncology. Immediately prior to that, Dr. Sisley served as Assoc. Prof. of Surgery in Augusta, GA at MCG division of Surgical Oncology.
